文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

盐敏感性与心肌纤维化:揭示隐匿的心血管重塑

Salt sensitivity and myocardial fibrosis: unraveling the silent cardiovascular remodeling.

作者信息

Mutengo Katongo Hope, Ngalamika Owen, Kirabo Annet, Masenga Sepiso K

机构信息

Department of Internal Medicine, Ministry of Health, Monze Mission Hospital, Monze, Zambia.

Department of Internal Medicine, School of Medicine, University of Zambia, Lusaka, Zambia.

出版信息

Front Pharmacol. 2025 Jun 13;16:1626492. doi: 10.3389/fphar.2025.1626492. eCollection 2025.


DOI:10.3389/fphar.2025.1626492
PMID:40584624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12202478/
Abstract

Salt sensitivity is a well-recognized contributor to cardiovascular risk, traditionally linked to elevated blood pressure. However, emerging evidence suggests that high dietary sodium may also promote myocardial fibrosis through non-hemodynamic mechanisms, including the activation of redox-sensitive and profibrotic pathways. Despite growing mechanistic insights, the connection between salt sensitivity and myocardial fibrosis remains underexplored, particularly in human studies. This review synthesizes current experimental and translational evidence linking dietary salt intake to myocardial fibrosis, with a focus on molecular signaling cascades, tissue sodium compartmentalization, and the clinical implications of salt-sensitive physiology. We discuss the relevance of these mechanisms to the development of diastolic dysfunction and their potential contribution to heart failure with preserved ejection fraction (HFpEF). In addition, we highlight findings from animal models and the emerging application of sodium magnetic resonance imaging (Na-MRI) as a novel imaging tool for visualizing myocardial sodium overload and its association with fibrotic remodeling. Finally, we explore future therapeutic strategies that extend beyond traditional antihypertensives, including mineralocorticoid receptor antagonists (MRAs), angiotensin receptor blockers (ARBs), sodium-glucose cotransport 2 (SGLT2) inhibitors, and sodium-modulating interventions. Together, these insights offer new opportunities for early detection and targeted treatment in salt-sensitive cardiovascular disease.

摘要

盐敏感性是心血管风险的一个公认因素,传统上与血压升高有关。然而,新出现的证据表明,高膳食钠摄入也可能通过非血流动力学机制促进心肌纤维化,包括氧化还原敏感和促纤维化途径的激活。尽管对其机制的认识不断增加,但盐敏感性与心肌纤维化之间的联系仍未得到充分探索,尤其是在人体研究中。本综述综合了目前将膳食盐摄入与心肌纤维化联系起来的实验和转化证据,重点关注分子信号级联、组织钠分隔以及盐敏感生理学的临床意义。我们讨论了这些机制与舒张功能障碍发展的相关性及其对射血分数保留的心力衰竭(HFpEF)的潜在贡献。此外,我们强调了动物模型的研究结果以及钠磁共振成像(Na-MRI)作为一种新型成像工具在可视化心肌钠过载及其与纤维化重塑关联方面的新兴应用。最后,我们探索了超越传统抗高血压药物的未来治疗策略,包括盐皮质激素受体拮抗剂(MRAs)、血管紧张素受体阻滞剂(ARBs)、钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和钠调节干预措施。这些见解共同为盐敏感性心血管疾病的早期检测和靶向治疗提供了新机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/59db94e1e20c/fphar-16-1626492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/1758502fc355/fphar-16-1626492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/fd209c6314e0/fphar-16-1626492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/a92c747f7370/fphar-16-1626492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/59db94e1e20c/fphar-16-1626492-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/1758502fc355/fphar-16-1626492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/fd209c6314e0/fphar-16-1626492-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/a92c747f7370/fphar-16-1626492-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de50/12202478/59db94e1e20c/fphar-16-1626492-g004.jpg

相似文献

[1]
Salt sensitivity and myocardial fibrosis: unraveling the silent cardiovascular remodeling.

Front Pharmacol. 2025-6-13

[2]
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Cochrane Database Syst Rev. 2018-6-28

[3]
Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women.

Cochrane Database Syst Rev. 2022-8-10

[4]
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Cochrane Database Syst Rev. 2021-10-25

[5]
Altered dietary salt intake for preventing diabetic kidney disease and its progression.

Cochrane Database Syst Rev. 2023-1-16

[6]
Renin inhibitors versus angiotensin receptor blockers for primary hypertension.

Cochrane Database Syst Rev. 2025-2-27

[7]
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.

Cochrane Database Syst Rev. 2022-2-24

[8]
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.

Diabetes Obes Metab. 2022-11

[9]
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.

Cochrane Database Syst Rev. 2025-5-6

[10]
Beta-blockers in patients without heart failure after myocardial infarction.

Cochrane Database Syst Rev. 2021-11-5

本文引用的文献

[1]
The role of estrogen in the sex difference for the risk factors of heart failure with preserved ejection fraction.

Biol Direct. 2025-3-10

[2]
Salt sensitivity of blood pressure: mechanisms and sex-specific differences.

Nat Rev Cardiol. 2025-2-21

[3]
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction.

Eur Heart J Suppl. 2025-2-19

[4]
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction.

Sci Rep. 2024-12-28

[5]
Evidence for Aldosterone Antagonism in Heart Failure.

Card Fail Rev. 2024-11-12

[6]
Inflammation and resolution in obesity.

Nat Rev Endocrinol. 2025-1

[7]
The Complex Interplay of TGF-β and Notch Signaling in the Pathogenesis of Fibrosis.

Int J Mol Sci. 2024-10-8

[8]
The aging heart in focus: The advanced understanding of heart failure with preserved ejection fraction.

Ageing Res Rev. 2024-11

[9]
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.

J Am Coll Cardiol. 2025-1-21

[10]
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.

J Am Coll Cardiol. 2024-10-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索